FIXX
Income statement / Annual
Last year (2024), Homology Medicines, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Homology Medicines, Inc.'s net income was -$47.73 M.
See Homology Medicines, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$1.16 M |
$3.21 M |
$33.97 M |
$2.70 M |
$1.67 M |
$3.68 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$578.00 K
|
$2.60 M
|
$9.54 M
|
$100.39 M
|
$89.40 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$578.00 K
|
$609.00 K
|
$24.43 M
|
-$97.69 M
|
-$87.73 M
|
$3.68 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0.5
|
0.19
|
0.72
|
-36.15
|
-52.66
|
1
|
0
|
0
|
| Research and Development Expenses |
$48.14 M
|
$62.00 M
|
$98.35 M
|
$93.09 M
|
$100.39 M
|
$89.40 M
|
$47.95 M
|
$21.38 M
|
$5.69 M
|
| General & Administrative Expenses |
$17.96 M
|
$31.26 M
|
$38.14 M
|
$36.84 M
|
$32.57 M
|
$22.21 M
|
$17.30 M
|
$8.28 M
|
$4.31 M
|
| Selling & Marketing Expenses |
$0.00
|
-$578.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.96 M
|
$30.68 M
|
$38.14 M
|
$36.84 M
|
$32.57 M
|
$22.21 M
|
$17.30 M
|
$8.28 M
|
$4.31 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$66.10 M
|
$92.68 M
|
$136.49 M
|
$129.92 M
|
$132.97 M
|
$111.61 M
|
$65.25 M
|
$29.66 M
|
$10.00 M
|
| Cost And Expenses |
$0.00
|
$93.26 M
|
$136.49 M
|
$129.92 M
|
$132.97 M
|
$111.61 M
|
$65.25 M
|
$29.66 M
|
$10.00 M
|
| Interest Income |
$0.00
|
$5.58 M
|
$3.23 M
|
$185.00 K
|
$1.57 M
|
$6.03 M
|
$4.35 M
|
$542.64 K
|
$24.20 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$578.00 K
|
-$129.96 M
|
$8.35 M
|
$7.97 M
|
$6.32 M
|
$1.29 M
|
$684.21 K
|
$239.80 K
|
| EBITDA |
-$66.10 M |
-$91.52 M |
-$133.28 M |
-$87.60 M |
-$122.30 M |
-$103.63 M |
-$60.28 M |
-$28.97 M |
-$9.76 M |
| EBITDA Ratio |
0
|
-79.17
|
-41.55
|
-2.58
|
-45.26
|
-62.2
|
-16.36
|
0
|
0
|
| Operating Income Ratio |
0
|
-79.67
|
-41.55
|
-2.82
|
-48.21
|
-65.99
|
-16.71
|
0
|
0
|
| Total Other Income/Expenses Net |
$20.02 M
|
$14.35 M
|
$134.48 M
|
$185.00 K
|
$1.57 M
|
$6.03 M
|
$4.35 M
|
-$333.37 K
|
$1.95 M
|
| Income Before Tax |
-$46.09 M
|
-$87.08 M
|
$1.20 M
|
-$95.76 M
|
-$128.69 M
|
-$103.92 M
|
-$57.22 M
|
-$29.99 M
|
-$8.05 M
|
| Income Before Tax Ratio |
0
|
-75.33
|
0.37
|
-2.82
|
-47.63
|
-62.37
|
-15.53
|
0
|
0
|
| Income Tax Expense |
-$21.00 K
|
$25.88 M
|
$715.00 K
|
-$185.00 K
|
-$1.57 M
|
-$6.03 M
|
$0.00
|
$0.00
|
-$24.20 K
|
| Net Income |
-$47.73 M
|
-$112.96 M
|
$483.00 K
|
-$95.58 M
|
-$127.13 M
|
-$97.89 M
|
-$57.22 M
|
-$29.99 M
|
-$8.05 M
|
| Net Income Ratio |
0
|
-97.72
|
0.15
|
-2.81
|
-47.05
|
-58.76
|
-15.53
|
0
|
0
|
| EPS |
-5.12 |
-351.57 |
1.51 |
-311.2 |
-498.41 |
-418.35 |
-360.7 |
-159.96 |
-77.86 |
| EPS Diluted |
-4.94 |
-351.57 |
1.51 |
-311.2 |
-498.41 |
-418.35 |
-360.7 |
-159.96 |
-77.86 |
| Weighted Average Shares Out |
$9.32 M
|
$321.30 K
|
$318.89 K
|
$307.13 K
|
$255.06 K
|
$233.99 K
|
$158.62 K
|
$187.49 K
|
$103.35 K
|
| Weighted Average Shares Out Diluted |
$9.66 M
|
$321.30 K
|
$318.89 K
|
$307.13 K
|
$255.06 K
|
$233.99 K
|
$158.62 K
|
$187.49 K
|
$103.35 K
|
| Link |
|
|
|
|
|
|
|
|
|
